Labcorp Holdings Inc.
LH- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0000920148
In the last 90 days, Labcorp Holdings Inc. insiders filed 0 open-market purchases and 6 sales; 1,061 institutions reported holding it in 13F filings for Q2 2026, worth $22.2B in total; Weitz Investment Management is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Labcorp Holdings Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 6 insiders, $3.27M in total
- Insiders trading
- 6
- Net value
- −$3.27M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Labcorp Holdings Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Oyegunwa Akinbolade | EVP, CIO & CTO | 5,064 | Sep 3, 2026 | 6 |
| Meltzer Jonathan C | EVP, COO | 3,620 | Sep 3, 2026 | 5 |
| Vaughn Bryan T | EVP and President, Diagnostics | 6,746 | Sep 3, 2026 | 6 |
| Caveney Brian J | EVP, Pres of BLS, CMO & CSO | 36,492 | Sep 3, 2026 | 6 |
| Anderson Kerrii B | Director | 6,563 | Aug 18, 2026 | 3 |
| Schechter Adam H | President & CEO | 102,565 | Aug 12, 2026 | 8 |
| Summy Amy B. | EVP, Chief Marketing Officer | 6,956 | Aug 6, 2026 | 5 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 1,770 | Aug 5, 2026 | 6 |
| Kyle Kathryn W | EVP, Chief Legal Officer | 3,904 | Jul 6, 2026 | 6 |
| Graham Anita Z | EVP, CHRO | 5,185 | Mar 30, 2026 | 4 |
| van der Vaart Sandra D | EVP, Corporate Affairs | 6,239 | Mar 30, 2026 | 4 |
| Schroeder Mark S | EVP, Pres Diagnostics & COO | 12,677 | Mar 30, 2026 | 3 |
| Bailey Megan D. | EVP, Pres, Central Labs & Intl | 4,851 | Mar 30, 2026 | 5 |
| Neupert Peter M | Director | 13,784 | Feb 13, 2026 | 2 |
| Kong Garheng | Director | 13,739 | Feb 13, 2026 | 2 |
| Parham Richelle P | Director | 3,366 | Feb 13, 2026 | 3 |
| Rothman Paul | Director | 2,571 | Feb 13, 2026 | 2 |
| Davis Jeffrey A. | Director | 5,460 | Feb 13, 2026 | 2 |
| Wengel Kathryn E | Director | 4,133 | Feb 13, 2026 | 2 |
| Wang Julia Aijun | Chief Financial Officer, EVP | 1,817 | Feb 13, 2026 | 3 |
| Kliphouse Kirsten Marie | Director | 3,160 | Feb 13, 2026 | 2 |
| Bulto Carulla Victor | Director | – | Feb 12, 2026 | 2 |
| Sampson John H | Director | – | Feb 12, 2026 | 1 |
| Gilliland Dwight Gary | Director | 6,656 | Aug 1, 2025 | 0 |
| Berberian Lance | EVP, Special Advisor, Strategy | 18,652 | Mar 31, 2025 | 0 |
| Eisenberg Glenn A | Executive Vice President | 37,920 | Mar 31, 2025 | 0 |
| DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | 5,461 | Mar 29, 2024 | 0 |
| Belingard Jean-Luc | Director | 17,781 | Feb 8, 2024 | 0 |
| Williams R Sanders | Director | 8,120 | Feb 8, 2024 | 0 |
| Kirchgraber Paul R | CEO, Covance Drug Development | 12,946 | May 23, 2023 | 0 |
| Seltz Judith C | EVP, CHRO | 4,182 | Apr 3, 2023 | 0 |
| Pike Thomas | Pres & CEO Clinical Business | – | Jan 11, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Berberian LanceEVP, CIO & CTO | SSale | −12.1K | $229.11 | −$2.77M | −43.2%15.9K after | 2 lots |
| May 16, 2024 (view filing) | May 14 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −2.00K | $210.83 | −$421.7K | −26.2%5.64K after | 2 lots |
| May 2, 2024 (view filing) | Apr 30-May 2 | 2 days | Anderson Kerrii BDirector | SSale | −500 | $202.12 | −$101.1K | −3.1%15.7K after | 2 lots |
| May 1, 2024 (view filing) | Apr 29 | 2 days | Wilkinson Peter JSVP, Chief Accounting Officer | SSale | −2.44K | $204.33 | −$498.4K | −53.9%2.09K after | |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Schroeder Mark SEVP, Pres Diagnostics & COO | SSale | −6.48K | $217.29 | −$1.41M | −56.3%5.04K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Summy Amy B.EVP, Chief Marketing Officer | SSale | −3.50K | $217.29 | −$760.5K | −46.8%3.98K after | 10b5-1 |
| Mar 29, 2024 (view filing) | Mar 28 | 1 day | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −3.55K | $216.74 | −$770.1K | −31.8%7.64K after | 10b5-1 |
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Schroeder Mark SEVP, Pres Diagnostics & COO | SSale | −5.05K | $218.45 | −$1.10M | −50.1%5.04K after | 10b5-1 |
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Summy Amy B.EVP, Chief Marketing Officer | SSale | −227 | $218.45 | −$49.6K | −5.6%3.86K after | 10b5-1 |
| Feb 22, 2024 (view filing) | Feb 21 | 1 day | Eisenberg Glenn AChief Financial Officer, EVP | SSale | −34.5K | $215.97 | −$7.45M | −59.4%23.6K after | 4 lots |
| Feb 22, 2024 (view filing) | Feb 21 | 1 day | DiVincenzo Jonathan P.EVP, Pres, Central Labs & Intl | SSale | −500 | $215.49 | −$107.7K | −12.8%3.40K after | |
| Feb 15, 2024 (view filing) | Feb 13 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −237 | $226.45 | −$53.7K | −3.0%7.64K after | 10b5-1 |
| Feb 9, 2024 (view filing) | Feb 8 | 1 day | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −259 | $222.06 | −$57.5K | −3.3%7.64K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −193 | $220.57 | −$42.6K | −2.5%7.64K after | 10b5-1 |
| Nov 20, 2023 (view filing) | Nov 16 | 4 days | Wilkinson Peter JSVP, Chief Accounting Officer | SSale | −1.38K | $210.71 | −$291.6K | −39.9%2.09K after | |
| Aug 10, 2023 (view filing) | Aug 8 | 2 days | Anderson Kerrii BDirector | SSale | −5.00K | $211.57 | −$1.06M | −24.7%15.3K after | |
| Jul 3, 2023 (view filing) | Jun 29 | 4 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −212 | $240.00 | −$50.9K | −2.7%7.60K after | 10b5-1 |
| May 23, 2023 (view filing) | May 19 | 4 days | Kirchgraber Paul RCEO, Covance Drug Development | SSale | −4.30K | $216.91 | −$932.7K | −24.9%12.9K after | |
| May 22, 2023 (view filing) | May 18 | 4 days | Schroeder Mark SEVP, Pres Diagnostics & COO | SSale | −1.50K | $216.77 | −$325.2K | −18.3%6.69K after | 10b5-1 |
| Apr 3, 2023 (view filing) | Mar 31 | 3 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −3.90K | $225.81 | −$880.0K | −36.8%6.69K after | 10b5-1 |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Kirchgraber Paul RCEO, Covance Drug Development | SSale | −8.00K | $250.58 | −$2.00M | −46.9%9.07K after | |
| Feb 16, 2023 (view filing) | Feb 14 | 2 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −309 | $247.63 | −$76.5K | −4.4%6.69K after | |
| Feb 9, 2023 (view filing) | Feb 7 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −219 | $243.01 | −$53.2K | −3.9%5.34K after | |
| Feb 9, 2023 (view filing) | Feb 7 | 2 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −409 | $243.01 | −$99.4K | −5.8%6.69K after | |
| Feb 6, 2023 (view filing) | Feb 3 | 3 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −173 | $253.90 | −$43.9K | −3.1%5.34K after | |
| Feb 6, 2023 (view filing) | Feb 3 | 3 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −324 | $253.90 | −$82.3K | −4.6%6.69K after | |
| Nov 10, 2022 (view filing) | Nov 8 | 2 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −1.12K | $232.67 | −$259.7K | −14.3%6.69K after | |
| Sep 28, 2022 (view filing) | Sep 26 | 2 days | Eisenberg Glenn AChief Financial Officer, EVP | SSale | −25.0K | $210.62 | −$5.27M | −47.9%27.2K after | 4 lots |
| Sep 13, 2022 (view filing) | Sep 7 | 6 daysLate | Caveney Brian JEVP, President of Diagnostics | PPurchase | +44.34 | $231.20 | +$10.3K | +0.3%14.3K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Eisenberg Glenn AChief Financial Officer, EVP | SSale | −32.1K | $253.94 | −$8.15M | −38.1%52.2K after | 3 lots |
| Aug 3, 2022 (view filing) | Aug 1 | 2 days | Wilkinson Peter JSVP, Chief Accounting Officer | SSale | −2.58K | $258.40 | −$665.6K | −57.7%1.89K after | 3 lots |
| Jun 14, 2022 (view filing) | Jun 7 | 7 daysLate | Caveney Brian JEVP, President of Diagnostics | PPurchase | +42.01 | $242.19 | +$10.2K | +0.3%14.2K after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −2.36K | $277.11 | −$652.9K | −26.3%6.61K after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −2.45K | $277.11 | −$678.6K | −31.7%5.29K after | |
| Mar 29, 2022 (view filing) | Mar 25 | 4 days | Williams R SandersDirector | SSale | −572 | $272.98 | −$156.1K | −8.2%6.43K after | |
| Mar 14, 2022 (view filing) | Mar 10 | 4 days | Summy Amy B.EVP, Chief Marketing Officer | SSale | −249 | $262.21 | −$65.3K | −49.9%250 after | |
| Feb 18, 2022 (view filing) | Feb 16 | 2 days | Neupert Peter MDirector | PPurchase | +3.50K | $263.66 | +$922.8K | +51.8%10.3K after | 3 lots |
| Feb 17, 2022 (view filing) | Feb 15 | 2 days | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −207 | $273.98 | −$56.7K | −3.0%6.61K after | |
| Feb 17, 2022 (view filing) | Feb 15 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −207 | $273.98 | −$56.7K | −3.8%5.29K after | |
| Feb 8, 2022 (view filing) | Feb 7 | 1 day | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −204 | $277.38 | −$56.6K | −3.0%6.61K after | |
| Feb 8, 2022 (view filing) | Feb 7 | 1 day | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −218 | $277.38 | −$60.5K | −4.0%5.29K after | |
| Feb 4, 2022 (view filing) | Feb 3 | 1 day | Schroeder Mark SEVP, President-Diagnostics Lab | SSale | −161 | $271.81 | −$43.8K | −2.5%6.40K after | |
| Feb 4, 2022 (view filing) | Feb 3 | 1 day | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −172 | $271.81 | −$46.8K | −3.2%5.29K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Gilliland Dwight GaryDirector | SSale | −500 | $302.26 | −$151.1K | −7.4%6.25K after | 4 lots |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | van der Vaart Sandra DEVP, Chief Legal Officer | SSale | −4.50K | $296.78 | −$1.34M | −46.1%5.26K after |